Predicting acute and late toxicity in prostate cancer stereotactic ablative radiotherapy: the role of dosimetric parameters and prostate volume
Strahlentherapie und Onkologie · 2025
DOI: 10.1007/s00066-024-02343-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Strahlentherapie und Onkologie, 2025. Verfasst von Gokhan Ozyigit und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey. gozyigit@hacettepe.edu.tr. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiosurgery, Prostate, Radiation Injuries. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hacettepe University.
Abstract (Originalsprache)
Purpose
Our objective was to identify the dosimetric parameters and prostate volume that most accurately predict the incidence of acute and late gastrointestinal (GI) and genitourinary (GU) toxicity in prostate cancer stereotactic ablative radiotherapy (SABR) treatments.
Methods
We conducted a retrospective analysis of 122 patients who received SABR for prostate cancer at our clinic between March 2018 and September 2022 using a five-fraction SABR regimen. The existing plans of these patients were re-evaluated according to our institutional protocols (Hacettepe University [HU-1] and HU-2) as well as PACE‑B, RTOG 0938, and NRG GU005 dose–volume constraints. Univariate and multivariate logistic regression analyses were performed using SPSS version 23.0 (IBM, Armonk, NY, USA).
Results
The median follow-up was 24.7 months (0.8–94.4 months). For acute GU toxicity, moderate-dose regions were predictive for grade 1–2 toxicity, while high-dose regions were more associated with grade 3–4 toxicity. For late GU toxicity, moderate–high-dose regions were predictive. For GI toxicity, moderate-dose regions were important for both acute and late toxicity. The HU protocol encompassed all significant dosimetric factors influencing toxicity outcomes. A prostate volume threshold of 60 cc was predictive of acute grade 3–4 GU toxicity.
Conclusion
Our study highlighted the critical role of moderate-dose regions for acute and late GI and GU toxicity. Prostate treatment plans should be rigorously evaluated, and moderate doses should be minimized. The HU protocol is an eligible choice for five-fraction SABR plans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey. gozyigit@hacettepe.edu.tr.
- Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
ORCID-Profile: Gokhan Ozyigit, Pervin Hurmuz, Melek Tugce Yilmaz
Förderung
- Hacettepe University
Zitieren
APA
Ozyigit, G., Hurmuz, P., Bayatfard, P., Tilki, B., Yedekci, Y., & Yilmaz, M. T. (2025). Predicting acute and late toxicity in prostate cancer stereotactic ablative radiotherapy: the role of dosimetric parameters and prostate volume. Strahlentherapie und Onkologie. https://doi.org/10.1007/s00066-024-02343-2
Vancouver
Ozyigit G, Hurmuz P, Bayatfard P, Tilki B, Yedekci Y, Yilmaz MT. Predicting acute and late toxicity in prostate cancer stereotactic ablative radiotherapy: the role of dosimetric parameters and prostate volume. Strahlentherapie und Onkologie. 2025. doi:10.1007/s00066-024-02343-2
BibTeX
@article{Ozyigit2025,
author = {Ozyigit, Gokhan and Hurmuz, Pervin and Bayatfard, Pantea and Tilki, Burak and Yedekci, Yagiz and Yilmaz, Melek Tugce},
title = {Predicting acute and late toxicity in prostate cancer stereotactic ablative radiotherapy: the role of dosimetric parameters and prostate volume},
journal = {Strahlentherapie und Onkologie},
year = {2025},
doi = {10.1007/s00066-024-02343-2}
}
EUVIMED